Farré M - Search Results

1

The Tryptophan System in Cocaine-Induced Depression.

Fonseca F, Mestre-Pintó JI, Gómez-Gómez À, Martinez-Sanvisens D, Rodríguez-Minguela R, Papaseit E, Pérez-Mañá C, Langohr K, Valverde O, Pozo ÓJ, Farré M, Torrens M, On Behalf Of Neurodep Group. Fonseca F, et al. Among authors: farre m. J Clin Med. 2020 Dec 19;9(12):4103. doi: 10.3390/jcm9124103. J Clin Med. 2020. PMID: 33352710 Free PMC article.

2

Flunitrazepam consumption among heroin addicts admitted for in-patient detoxification.

San L, Tato J, Torrens M, Castillo C, Farré M, Camí J. San L, et al. Among authors: farre m. Drug Alcohol Depend. 1993 May;32(3):281-6. doi: 10.1016/0376-8716(93)90093-6. Drug Alcohol Depend. 1993. PMID: 8102333

3

Abuse liability of flunitrazepam among methadone-maintained patients.

Farré M, Terán MT, Roset PN, Mas M, Torrens M, Camí J. Farré M, et al. Psychopharmacology (Berl). 1998 Dec;140(4):486-95. doi: 10.1007/s002130050793. Psychopharmacology (Berl). 1998. PMID: 9888625 Clinical Trial.

4

3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics.

Hernández-López C, Farré M, Roset PN, Menoyo E, Pizarro N, Ortuño J, Torrens M, Camí J, de La Torre R. Hernández-López C, et al. Among authors: farre m. J Pharmacol Exp Ther. 2002 Jan;300(1):236-44. doi: 10.1124/jpet.300.1.236. J Pharmacol Exp Ther. 2002. PMID: 11752122 Clinical Trial.

5

Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis.

Farré M, Mas A, Torrens M, Moreno V, Camí J. Farré M, et al. Drug Alcohol Depend. 2002 Feb 1;65(3):283-90. doi: 10.1016/s0376-8716(01)00171-5. Drug Alcohol Depend. 2002. PMID: 11841899

6

Maintenance buprenorphine for opioid users.

Farré M, Torrens M. Farré M, et al. Lancet. 2003 May 31;361(9372):1906-7; author reply 1907-8. doi: 10.1016/S0140-6736(03)13512-X. Lancet. 2003. PMID: 12788595 No abstract available.

7

Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics.

Farré M, de la Torre R, Mathúna BO, Roset PN, Peiró AM, Torrens M, Ortuño J, Pujadas M, Camí J. Farré M, et al. Psychopharmacology (Berl). 2004 May;173(3-4):364-75. doi: 10.1007/s00213-004-1789-7. Epub 2004 Apr 8. Psychopharmacology (Berl). 2004. PMID: 15071716 Clinical Trial.

8

Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis.

Torrens M, Fonseca F, Mateu G, Farré M. Torrens M, et al. Among authors: farre m. Drug Alcohol Depend. 2005 Apr 4;78(1):1-22. doi: 10.1016/j.drugalcdep.2004.09.004. Epub 2004 Nov 11. Drug Alcohol Depend. 2005. PMID: 15769553 Review.

9

MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers.

de la Torre R, Farré M, Mathúna BO, Roset PN, Pizarro N, Segura M, Torrens M, Ortuño J, Pujadas M, Camí J. de la Torre R, et al. Among authors: farre m. Eur J Clin Pharmacol. 2005 Aug;61(7):551-4. doi: 10.1007/s00228-005-0965-y. Epub 2005 Jul 23. Eur J Clin Pharmacol. 2005. PMID: 16041599 Clinical Trial. No abstract available.

10

Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics.

Abanades S, Farré M, Segura M, Pichini S, Barral D, Pacifici R, Pellegrini M, Fonseca F, Langohr K, De La Torre R. Abanades S, et al. Among authors: farre m. Ann N Y Acad Sci. 2006 Aug;1074:559-76. doi: 10.1196/annals.1369.065. Ann N Y Acad Sci. 2006. PMID: 17105953 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

700 results

Search Page